Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
HUNTSVILLE, Ala., July 24, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the “Company”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ...
-
HUNTSVILLE, Ala., July 22, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the “Company”) (NYSE American: SER), a clinical-stage biotechnology company advancing its proprietary POZ...
-
Data Safety Monitoring Committee completed initial review of sentinel dosing observations and recommended continued dosing in Cohort 1 - Dosing of additional patients in Cohort 1 is underway at sites...
-
Phase 1b Registrational Clinical Study of SER-252 Underway in Advanced Parkinson’s Disease; TFL data from the SAD study arm targeted for first half of 2027 - – Closed $21.2 million private placement...
-
HUNTSVILLE, AL, March 24, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug...
-
- First tranche of $15 million expected to close on March 20, 2026; second tranche of up to $15 million available, for up to $30 million in total proceeds from the sale of common stock and pre-funded...
-
- Blinded evaluation of safety and tolerability data by the Safety Monitoring Committee from Cohort 1 and advancement to Cohort 2 is expected in 3Q 2026 – - Advancement reflects continued execution...
-
- First patient successfully enrolled in global registrational study in Australia - Operational presence in Australia positions Serina to advance enrollment in Cohort 1- Company remains on track for...
-
HUNTSVILLE, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the "Company") (NYSE American: SER), a clinical-stage biotechnology company advancing its lead Investigational...
-
HUNTSVILLE, AL., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug...